Literature DB >> 4015309

A comparison of two diagnostic methods. Clinical ICD diagnoses vs DSM-III and Research Diagnostic Criteria using the Diagnostic Interview Schedule (version 2).

H U Wittchen, G Semler, D von Zerssen.   

Abstract

In the context of a seven-year follow-up study, 171 former psychiatric inpatients and 158 subjects from the general population were interviewed twice, first with the German version of the Diagnostic Interview Schedule (DIS) (version 2), and second with a clinical interview using the Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMDP) checklist to assign a clinical International Classification of Diseases (eighth revision) (ICD-8) diagnosis, independent of the DIS. With the clinicians' ICD-8 diagnosis as a measure of the quality of the DIS, the results indicate a sufficiently high overall specificity and sensitivity of the DIS as a case-finding instrument in a general population survey, and a surprisingly high concordance of most DIS diagnostic classes with comparable ICD diagnoses. Only for panic disorders (possibly due to different symptom and time criteria) and schizophrenia (possibly due to the strict probe system, the dependence on self-reports, and time criteria) was low sensitivity found. Because there is no DIS diagnostic category comparable with ICD-8 unipolar affective psychosis, a meaningful comparison of this ICD category with Research Diagnostic Criteria and DSM-III was not possible.

Entities:  

Mesh:

Year:  1985        PMID: 4015309     DOI: 10.1001/archpsyc.1985.01790300045005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  19 in total

1.  Why discrepancies exist between structured diagnostic interviews and clinicians' diagnoses.

Authors:  V Kovess; O Sylla; L Fournier; V Flavigny
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1992-08       Impact factor: 4.328

2.  Evidence for the continuous latent structure of mania in the Epidemiologic Catchment Area from multiple latent structure and construct validation methodologies.

Authors:  J J Prisciandaro; J E Roberts
Journal:  Psychol Med       Date:  2010-05-27       Impact factor: 7.723

3.  Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study.

Authors:  H U Wittchen; C A Essau; D von Zerssen; J C Krieg; M Zaudig
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

4.  The National Institute of Mental Health--Epidemiologic Catchment Area (NIMH-ECA) program. Background, preliminary findings and implications.

Authors:  G L Klerman
Journal:  Soc Psychiatry       Date:  1986

Review 5.  Psychiatric epidemiology in cross-cultural perspective: a review.

Authors:  Y A Aderibigbe; S K Adityanjee
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

6.  The frequency of social dysfunction in a general population sample and in patients with mental disorders. A comparison using the Social Interview Schedule (SIS).

Authors:  H Hecht; H U Wittchen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1988-01       Impact factor: 4.328

7.  Phobia: prevalence and risk factors.

Authors:  J H Boyd; D S Rae; J W Thompson; B J Burns; K Bourdon; B Z Locke; D A Regier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1990-11       Impact factor: 4.328

8.  Social disorder and diagnostic order: the US Mental Hygiene Movement, the Midtown Manhattan study and the development of psychiatric epidemiology in the 20th century.

Authors:  Dana March; Gerald M Oppenheimer
Journal:  Int J Epidemiol       Date:  2014-07-15       Impact factor: 7.196

9.  Typus melancholicus as a personality characteristic of migraine patients.

Authors:  M L Schäfer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

10.  Suicidal ideation and suicide attempts: comorbidity with depression, anxiety disorders, and substance abuse disorder.

Authors:  T Bronisch; H U Wittchen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.